...
首页> 外文期刊>European journal of clinical pharmacology >Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature.
【24h】

Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature.

机译:产品特征摘要中的信息不足会妨碍药物相互作用的最佳管理:与文献证据进行比较。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To compare comprehensiveness and accuracy of drug interaction information in the German summary of product characteristics (SPC) with current evidence from the literature and to evaluate the SPC's usefulness with respect to management of drug interactions.METHODS: Information on clinically relevant drug interactions was compared between the SPC and three standard information sources on drug interactions (DRUGDEX, Hansten/Horn's Drug Interactions Analysis and Management, Stockley's Drug Interactions) according to five consecutive criteria (inclusion, appropriateness of class labelling, effect description, management recommendation, explicit dose adjustment). Using medication data of an outpatient population (n=4,949), we determined what percentage of insufficiently characterized combinations indeed occurred in outpatients treated with combination drug therapy.RESULTS: Only for 33% (192/579) of the evaluated combinations did SPCs provide drug interaction information equivalent to the evidence from the published literature. Of the clinically relevant drug interactions, 16% were completely missing and 51% were insufficiently characterized compared with standard sources. Explicit management recommendations were either missing or differed from standard sources in 18% of the evaluated pairs of compounds. Of these missing or insufficiently characterized combinations, 12% (47/387) were indeed prescribed to outpatients. Those drug combinations for which the interaction potential was not mentioned in the SPC were received by 0.6% (32/4,949) of patients, and 4% (192/4,949) of patients received combinations that had insufficiently characterized drug interactions.CONCLUSIONS: If physicians only rely on SPC information for drug interactions, adverse events due to lacking management recommendations may occur. To meet the SPCs claim of being the basis of information for health professionals on how to use medicinal products safely and effectively, information on drug interactions should be thoroughly up-dated andexpanded.
机译:目的:比较德国产品特征摘要(SPC)中药物相互作用信息的全面性和准确性与文献中的最新证据,并评估SPC在管理药物相互作用方面的有用性。方法:临床上有关药物相互作用的信息根据五个连续的标准(包括,类别标签的适当性,作用说明,管理建议,明确的剂量调整),将SPC与有关药物相互作用的三个标准信息源(DRUGDEX,Hansten / Horn的药物相互作用分析和管理,Stockley的药物相互作用)进行了比较)。利用门诊患者的药物数据(n = 4,949),我们确定了在接受联合药物治疗的门诊患者中确实出现了表征不足的组合的百分比。结果:仅33%(192/579)的评估组合中SPC提供药物相互作用信息等同于已发表文献中的证据。与标准来源相比,在临床相关药物相互作用中,有16%完全缺失,而51%表征不足。在18%的评估化合物对中,没有明确的管理建议或与标准来源不同。在这些缺失或特征不足的组合中,确实有12%(47/387)开给了门诊病人。 SPC中未提及其相互作用潜力的那些药物组合被0.6%(32 / 4,949)的患者接受,而4%(192 / 4,949)的患者接受的药物相互作用特征不足的结论。仅依靠SPC信息进行药物相互作用,可能会由于缺乏管理建议而发生不良事件。为了满足SPC声称是卫生专业人员有关如何安全有效地使用药品的信息的基础,应该彻底更新和扩展有关药物相互作用的信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号